Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.
Products, services, technology
The First-in-Class radioligand differentiates from competition:
- New target, expressed in cancer cells and in tumor-associated growing blood vessels
- Selective small molecule ligand with long residence time on the target
- The specially designed linker defines an excellent in vivo profile
Cooperation possibilities
Based on its proprietary linker platform Amphilix has the potential to collaborate with other companies working on drug-drug conjugates to create molecules with optimal target product profiles. Examples include radioligand therapies, PROTACs, etc.
- http://amphilix.com
- +41 79 790 89 48
- Send an email
- Guido Koch
Some insights
The new Amphilix radioligand therapy will provide a treatment option for cancer sufferers who are refractory to all current treatments. Our goal is to provide progression-free survival for thousands of cancer patients.
We have successfully demonstrated the our RLT design and synthesis platform effectively translates in vivo.
Entrepreners that drive projects which lead to game changing therapies with strong benefits for patients.
Together we bring decades of experience in drug discovery and development into the company. We have successfully contributed to many clinical candidates and marketed products. In the future we wish to integrate AI identifying new molecular targets and for patient selection.
We are generating images of tumors and know how to selectively kill the tumours.
Providing support in early stage financing to accelerate innovation.
Investors (both private and VC) and potential partnering / licensing companies
